175211-40-2

Upstream product

• 76387-70-7 (S)-3-amino-2-tert-butoxycarbonylaminopropionic acid 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 192754-23-7 (3S)-2-Oxo-3-benzoylamino-5-(3-phenylpropionyl)-2,3,4,5-tetrahydro-1H-1,5-benzo diazepine-1-acetic acid methyl ester 
• 192755-59-2 [3-benzoylamino-2-oxo-5-(3-phenyl-propionyl)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-acetic acid 
• 192754-25-9 (3S)-2-oxo-3-(benzoylamino)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-acetic acid methyl ester 

Relevant academic research and scientific papers

Inhibitors of interleukin-1beta converting enzyme

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

Inhibitors of interleukin-1β Converting enzyme inhibitors

The present invention relates to pyradazino[1,2-a][1,2]diazepine-1-carboxamide compounds of formula: which compounds are inhibitors of interleukin-1beta converting enzyme.